





Rection/Amott B/AB3 A 1.28.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Zoltan Nagy

Serial No: 10/001,934

Filed:

November 15, 2001

For:

Human Polypeptides Causing or Leading to the killing of Cells Including Lymphoid Tumor cells Attorney Docket No.

GPCG-P01-00

Art Unit:

1642

Examiner:

Canella, Karen A.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

December 3, 2002

Date of Signature and of Mail Deposit

Joanne Ryan

Assistant Commissioner of Patents Washington, D.C. 20231

REPLY TO RESTRICTION REQUIREMENT

Sir:

Please enter the following amendments:

In the claims:

- 12. (Amended) The composition of claim 11, wherein said activated lymphoid cells are lymphoid tumor cells representing a disease selected from B cell non-Hodgkin lymphoma, B cell lymphoma, B cell acute lymphoid leukemia, Burkitt lymphoma, Hodgkin lymphoma, hairy cell leukemia, acute myeloid leukemia, T cell lymphoma, T cell non-Hodgkin lymphoma, chronic myeloid leukemia, chronic lymphoid leukemia, and multiple myeloma.
- 51. (Amended) The use according claim 49 or 50, wherein said treatment is the treatment of a disorder selected from B cell non-Hodgkin lymphoma, B cell lymphoma, B cell acute lymphoid leukemia, Burkitt lymphoma, Hodgkin lymphoma, hairy cell leukemia, acute

9001650_1